Related Experiment Video
Updated: Aug 11, 2026

CT-guided Preoperative Localization of Pulmonary Nodules Using a Glucose Test and Tissue Adhesive
Published on: January 30, 2026
AI-Assisted Papillary Thyroid Carcinoma Localization on Cervical Non-contrast CT: A Multicenter Validation and
Hao Wang1, Xuan Wang2, Zhi-Lin Chen2
1Department of Radiology, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, 210031, People's Republic of China.
None:
Accurate preoperative localization and 3D anatomical assessment of papillary thyroid carcinoma (PTC) are critical for surgical decision-making. Cervical non-contrast CT (NCCT) avoids iodinated contrast-related risks but has limited PTC lesion conspicuity, while first-line ultrasound suffers from operator dependence and incomplete 3D anatomical information. We developed a 3D full-resolution (fullres) nnU-Net model for joint thyroid and PTC segmentation on cervical NCCT, and conducted a pilot reader study to evaluate its auxiliary value for a junior and a senior radiologist. This multicenter retrospective study included 300 cases for model training, 120 temporal and 100 external test cases. Model performance was assessed via standard segmentation metrics, and the optimal model was packaged as a standalone executable Windows software. The 3D fullres model significantly outperformed 2D and single-label models for both PTC and thyroid segmentation (all P < 0.001). AI assistance significantly improved the diagnostic sensitivity of the participating junior radiologist (P < 0.001) and reduced active human reading time by > 40% for both readers, while the human-in-the-loop workflow effectively mitigated the model's inherent false-positive risk. This first NCCT-based 3D nnU-Net joint segmentation model improves the PTC diagnostic efficiency and sensitivity of the two participating radiologists, with an open-source standalone executable software providing a novel contrast-free tool to assist in regional PTC localization prior to surgery. Trial Registration: retrospectively registered in the Chinese Clinical Trial Registry (ChiCTR2500097848) on 2025-02-26.

